Overview

Bioequivalence of Telmisartan / HCTZ Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To establish the bioequivalence of 80 mg telmisartan/12.5 mg HCTZ fixed dose combination vs. its monocomponents
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Hydrochlorothiazide
Telmisartan